Abstract
Introduction Brentuximab vedotin (BV) and the PD-1 inhibitors, pembrolizumab and nivolumab, have dramatically improved therapeutic options in relapsed and refractory classic Hodgkin. More recently, BV-plus doxorubicin, vinblastine and dacarbazine (AVD) has emerged as a standard upfront regimen in patients with advanced stage disease. In addition, recent phase 2 trials have demonstrated promising results combining these novel agents with chemotherapy in the upfront setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
